VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15Vall d'Hebron hosted an international symposium of neuromonitoring and neurocritical patients (25/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=242&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0242\2014_0242_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Neurotraumatology and Neurosurgery Unit (UNINN) at Vall d’Hebron Institute of Research (VHIR) organized the XVI International Symposium on Neuromonitoring and Neurocritical Patients, which took place in Barcelona from the 18 to the 22 of November. During 5 days, the Altimara Hotel was the meeting point of more than 450 multidisciplinary professionals in the diagnosis and treatment of neurocritical patients and those with traumatic brain injury. The opening lecture of the symposium was carried out by Dr. Douglas H. Smith, Director of the Penn Center for Brain Injury and Repair of the Pennsylvania University. He talked about diffuse axonal damage after traumatic brain injury. The congress also included the XI Course on nursing care in neurocritical patients, accredited by the Consell Català de Formació Continuada de les Professions Sanitàries. </td></tr></table>comunica@vhir.org (VHIR)Tue, 25 Nov 2014 00:00:00 GMTResearchers identify a gene associated with susceptibility to cervical artery dissection (24/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=240&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0240\2014_0240_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the International Stroke Genetics Consortium, in which participate Dr. Joan Montaner and Dr. Israel Fernández Cadenas from the Neurovascular Diseases group at Vall d’Hebron Institute of Research (VHIR), have discovered the association of a gene, called PHACTR1, with the risk of suffering cervical artery dissection. The results have been published in Nature Genetics. European and American researchers screened the entire genome of 1,400 patients with cervical artery dissection, some of them treated at Vall d’Hebron, and 14,000 referents without this disease. The aim of the study was to identify genes predisposing to this disease in order to better understand its mechanisms and improve prevention strategies. Thanks to this in-depth analysis, which is the largest carried out ever, Dr. Israel Fernández Cadenas, researchers from VHIR and the Fundació de la Docència i Recerca MutuaTerrassa, assures that they have discovered that “individuals carrying a certain genetic variant in the PHACTR1 gene are more likely to suffer this disease that represents one of the main causes of stroke among young people”. In a previous study in which also participated VHIR researchers, this genetic variant had already been associated with people with higher risk of suffering migraine. It was known that migraine was a risk factor to suffer cervical artery dissection, but there was not any biological connection between these two diseases. Cervical artery dissection is caused by a tear in a brain supplying artery wall (carotid or vertebral) that can lead to compression of adjacent nerves and to blood clotting within the artery, potentially causing occlusion of downstream vessels and brain infarction. Despite its low prevalence –it affects 2,6 out of 100,000 people, it has serious effects in the health of the survivors. According to Dr. Joan Montaner, “understanding the mechanisms by which this region of the genome appears to influence key vascular fun</td></tr></table>comunica@vhir.org (VHIR)Mon, 24 Nov 2014 00:00:00 GMTVHIR celebrates 20 years of excellence in research (21/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=238&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0238\2014_0238_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) celebrated its 20th anniversary with an academic event that took place on Friday at the Pavelló Docent building, in front of over 200 people who are part of its history. On Thursday evening, promoters and authorities that participated in VHIR’s foundation, as well as donors, private companies who support the Instititute and technological partners, participated in an institutional dinner at Cosmocaixa. In both events, VHIR presented a video of its history. The academic event paid tribute to the key researchers in the foundation of the Institute: Dr. Simó Schwartz, HUVH’s first Research Director, Dr. Jordi Soler i Soler, former head of the Cardiology Service, Dr. Joan Ramon Malagelada, former head of the Gastroenterology Service, Dr. Jaume Guàrdia, former head of the Liver Diseases Group, and Dr. Àngel Ballabriga (1920-2008), former Director of the Children’s Hospital. Special mention was also given to people who have contributed to the center’s management during the past 20 years. This would be the case of former directors, –Dr. Carles Miquel, Dr. David García Dorado, Dr. José María Sáez as a posthumous title, and Dr. Juan Emilio Feliu– Trustees’ presidents or vice-presidents –Marina Geli, Dr. José Luis Sancho, and Dr. Jaume Raventós– and presidents of the Scientific Internal Committee that still are connected to VHIR –<span style=</td></tr></table>comunica@vhir.org (VHIR)Fri, 21 Nov 2014 00:00:00 GMTMutual Médica grants a study conducted by Dr. Marc Ramentol (19/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=241&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0241\2014_0241_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Marc Ramentol, researcher from the Systemic Diseases group at Vall d’Hebron Institute of Research (VHIR), has been granted with the Mutual Médica 2014 call, endowed with 4,000 euros, to investigate whether the persistent symptoms in the remission phase of Churg-Strauss syndrome are caused by an autoimmune expression of the disease. In the ceremony award, VHIR researcher highlighted the “rigorousness and the impartiality of the jury in the selection of the projects submitted, which means a great reputation for the young researchers awarded”. The eosinophilic granulomatosis with polyangiitis or Churg-Strauss syndrome is a systemic rare disease, with a prevalence of 2-6 cases out of one million people, which usually appears in patients who had previously suffered allergic asthma. </td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Nov 2014 00:00:00 GMTVHIR's biobank at a doctor's click (19/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=237&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0237\2014_0237_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The biobank from the Vall d’Hebron University Hospital has implemented a new system in order to ease and speed up the reception of blood and urine samples extracted at the hospital in order to use them in research. This new proceeding, which is integrated in the hospital’s circuit, makes easier for the doctor to ask for a Biobank analysis of a sample, as it’s only one click away, and always with the patients consent. Thanks to this new system, the samples will arrive correctly labeled and work will be easier for the researchers, who were the ones in charge of asking the medical staff to extract and send the samples for their studies. The Cardiocirculatory Pathology group, headed by Dr. David García-Dorado, is already taking profit of this system. Actually, the Cardiology Bank of the Biobank is integrated within  healthcare and research activity from the Cardiology service and is a key piece of the PRECISED project; an integrated excellence project from Instituto de Salud Carlos III, in which eight VHIR groups work to prevent isquemic cardiovascular accidents in diabetic patients. For Dr. García-Dorado, the start of the Cardiology Bank “opens new horizons for cardiovascular research in the molecular medicine era, which is a remarkable landmark in our group’s history”. </td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Nov 2014 00:00:00 GMTThe Health Care research group receives the prize to the best oral communication in the 18th International Nursing Research Conference (18/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=239&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0239\2014_0239_IMATGE.JPG" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Health Care group research group, led by Dr. Carmen Fuentelsaz, has been awarded the best oral communication in the 18th International Nursing Research Conference, held in Vitoria-Gasteiz. The award-winning work, “Blood extractions in critical patients as a cause of&nbsp; anemization”, is the fruit of six years of work at VHIR under the supervision of Anabel Solsona, Maria del Mar Eseverri, Mercedes Garrido, Maria Alba Riera, Jordi Gómez, Montserrat Lolo, Maria Agustina Paricio, Dina Butrón and Elisabeth Gallart. The Conference, organized by the Health Care research unit at the Instituto de Salud Carlos III, is the most important meeting in health care research taking place in Spain. In the present edition 433 research projects were presented, almost all of them developed by nursing professionals from 23 different countries, amongst which Catalunya stands out as the one that presented more projects, with a total of 77. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTSOM Biotech and the Vall d'Hebron Hospital have initiated a clinical trial in patients using a new repositioned drug for amyloidosis (18/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=235&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0235\2014_0235_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> SOM Biotech, located at the Parc Científic de Barcelona, has initiated the clinical phase of an innovative oral therapy for transthyretin amyloidosis (ATTR): compound SOM0226, a reprofiled drug developed entirely by the biopharmaceutical company. The phase IIa proof-of-concept trial in humans is being conducted at the Vall d'Hebron University Hospital, coordinated by Dr. Josep Gámez from the Peripheral Nervous System research group, and the treatment has already been administered to the first patients. The hospital will assume, jointly with the biotech, the risks and return on investment of the development of the drug, with the recent support from the Spanish Ministry of Economy. Transthyretin amyloidosis is a rare disabling disease with a severe prognosis that primarily affects the peripheral nervous system and the heart and, in some cases, is inherited from parents to children. The disease develops when the liver and other parts of the body produce the mutated protein transthyretin (TTR), causing a number of aggregates that are deposited into multiple organs. This excessive accumulation of protein, known as amyloid deposits,causes local cell damage that presents with a variety of clinical symptoms. These symptoms include severe cardiac and neurological problems that lead to the death of the patient within a period of 5 to 15 years. “Currently there is no other drug undergoing marketing approval for transthyretin amyloidosis in Europe. The only treatment available is a drug discovered in the United States (with the exorbitant price of more than 140,000 € per patient and per year) and liver transplantation, suitable only for a particular population group and with very high social and health costs", says Dr. Raúl Insa, founder and CEO of SOM Biotech. SOM0226 is a potent inhibitor of the amyloidogenic process with an innovative dual mechanism of action: as stabilizer of the transthyretin protein and disruptor of the fibers once they are deposited into the tissues. To cut it short, it stops progression and reverts the disease. This drug may also be effective against the 4 variants of transthyretin amyloidosis - polyneuropathic, cardiac, senile systemic and the CNS selective - including the more advanced stages of the disease. As a consequence, "this new therapeutic alternative will not only be able to confront Transthyretin amyloidosis but will also be able to prevent its progression, avoiding the formation of amyloid fibers”, remarks Dr. Gámez. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTVall d'Hebron researchers participate in the annual meeting of the REIPI (18/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=236&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0236\2014_0236_IMATGE.bmp" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the groups of infectious diseases and microbiology at the Vall d’Hebron Institute of Research (VHIR) have participated in the annual meeting of the Spanish net of research in infectious pathology (REIPI). In the meeting, that has reached its seventh edition and this year coincided with the European Antibiotic Awareness Day, experts discussed the recommendations of the European Centre for Disease Prevention and Control about the prudent use of antibiotics. This meeting is an opportunity to launch a global appeal for the problem of antibiotic resistance. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTExperts in congenital bone marrow failure meet in VHIR (17/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=234&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0234\2014_0234_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Over 70 experts in bone marrow failure field, both national and international, met last Friday, 14th November, in the XXth Pediatric Oncology and Hematology Update Course organized by the Vall d’hebron Institut de Recerca (VHIR). The specialists addressed the latest news in research and clinical practice of these illnesses, deepening the knowledge and diagnostic of population under the risk of suffering cancer. The Research team in Child Cancer, headed by Dr. Josep Sánchez de Toledo, organized once again this meeting, reference in the field. The congress day concluded with Body-Cell Percussion’s performance, by Santi Serratosa and Mariona Castells.  </td></tr></table>comunica@vhir.org (VHIR)Mon, 17 Nov 2014 00:00:00 GMTVHIR researchers discover why the individuals with Down Syndrome have more predisposition to suffer autoimmune diseases (12/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=233&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0233\2014_0233_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A team of researchers of the Immunology group at Vall d’Hebron Institute of Research (VHIR) have discovered that an autoimmune regulator protein, called AIRE, is less expressed in individuals with Down Syndrome. This finding explains why the people with this syndrome have more predisposition to suffer autoimmune diseases. For the study, published in the Journal of Immunology, VHIR researchers used the major collection of thymus samples collected until now. Specifically, they analyzed samples from 19 individuals with Down Syndrome and congenital heart disease, collected since 1995 at the Pediatric Surgery unit of the Vall d’Hebron University Hospital. All thymus were removed following cardiac surgery because in this type of interventions the organ can’t be reintroduced. All samples were compared with the samples of patients with congenital heart disease but without Down Syndrome. The AIRE protein is codified on chromosome 21, which is tripled in individuals with Down Syndrome. Despite having three copies of the chromosome, they have more predisposition to suffer autoimmune diseases such as diabetes, celiac disease and hypothyroidism. To determine which is the role of AIRE in these individuals, Vall d’Hebron researchers analyzed its expression in the thymus. “Contrary to what we expected, we saw that in patients with Down Syndrome the protein is expressed in lower levels that in the rest of the people”, assured Dr. Roger Colobran, main author of the study. As a consequence, the expression of the specific genes that depend on this protein is also reduced, and this produces the central tolerance failure that takes place in the thymus. The origin of many autoimmune diseases is in the thymus, which is the organ of the immune system where the T lymphocytes, that coordinate the immune response, are developed. AIRE controls the mechanism that educates the T lymphocytes to attack external organisms such as virus, bacteria, fungus or parasites, instead of the own cells of the body. However, when this protein is less expressed, there is a central tolerance failure and T cells attack the own cells, which can cause ultimately an autoimmune disease. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Nov 2014 00:00:00 GMTCAMFIC allocates the 0.7% of its budget on a project led by VHIR and PROSICS in Angola (12/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=176&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0176\2014_0176_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Society for Family and Community Medicine (CAMIFIC) has donated nearly 12,000 euros, which is the 0.7% of its budget, to the project “Improvement of the treatment and quality of life of patients with tuberculosis in an area of Angola with high prevalence of the disease”, led by researchers from Vall d’Hebron Institute of Research (VHIR) and the International Health Program of the Catalan Institute of Health (PROSICS). The society concluded in a statement that the project was awarded for its research dimension, its commitment to telemedicine and its orientation towards the health co-development. The study is carried out at VHIR by the groups of Infectious Diseases and Microbiology. Since 2008, researchers and clinicians from Vall d’Hebron have worked closely with the Nossa Senhora da Paz Hospital, located in the centre-east of Angola. Since then, they are maintaining a telemedicine program to share clinical cases, and conducting several studies about the resistance to tuberculosis, the epidemiology of schistosomiasis, and the relationship between malaria and child mortality. A couple of months ago, they installed in Angola the first automatic system to diagnose multidrug-resistant tuberculosis, thanks to an agreement with the Probitas Foundation. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Nov 2014 00:00:00 GMTDr. Josep Vaqué is awarded with the Semmelweis prize (11/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=232&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0232\2014_0232_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Vaqué, researcher of the Epidemiology and Public Health group at Vall d’Hebron Institute of Research (VHIR) and consultant physician of the same service at the hospital, has received the Semmelweis prize by the Spanish society of preventive medicine, public health and hygiene. The organization has awarded him for his study on the prevalence of hospital-acquired infections in Spain and for his commitment with the development and consolidation of the scientific society. He has coordinated since 1990 this annual study that is carried out in nearly 260 Spanish hospitals to determine the impact of the nosocomial infections in each centre. During the award ceremony, hosted last Friday at the Spanish Department of Health, Social Policy and Equality, Dr. Vaqué assured that “the EPINE study has become a very useful tool for the management of the hospitals, to improve the quality in the health care, and to ease the training of the staff in terms of surveillance, prevention and the control of nosocomial infections”. According to the latest results of the EPINE study, the 5.6% of the inpatients in 2014 got infected in the hospital, compared with the 8.5% in 1990. For Dr. Vaqué, these results show that “hospitals offer every year more security and quality in the control of nosocomial infections, which are still a common problem”. </td></tr></table>comunica@vhir.org (VHIR)Tue, 11 Nov 2014 00:00:00 GMTDr. Schwartz participates in the development of a strategic plan for innovation in nanotechnology in Argentina (06/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=231&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0231\2014_0231_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Simó Schwartz, coordinator of the CIBBIM-Nanomedicine at the Vall d’Hebron Institute of Research (VHIR), has advised the government of Argentina to develop a strategic plan of innovation in the field of nanomedicine and nanotechnology. The international consortium that has guided the government is also participated by the Institut de Bioenginyeria de Catalunya and the Universidad Nacional del Mar del Plata. After identifying the priority lines of research, development and innovations in this field, VHIR researchers have suggested specific action lines as well as political instruments required to implement them through the National plan of Science, Technology and Innovation 2005-2030. Among the main recommendations, there is the creation of national centers, the promotion of clusters, increasing public investments in equipment and R&amp;D&amp;I projects, promotion of entrepreneurship, speeding up import procedures, and the implementation of strategic monitoring systems to identify and create opportunities. Dr. Schwartz will also participate in the follow up of the project, which has received the technical support of IALE Tecnología, and has been funded by the Argentine government and the World Bank. </td></tr></table>comunica@vhir.org (VHIR)Thu, 6 Nov 2014 00:00:00 GMTVHIR is awarded with two 'Premios Mejores Ideas 2014' (04/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=230&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0230\2014_0230_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Ferran Morell, head of the Pneumology group at Vall d’Hebron Institute of Research (VHIR), was awarded with one of the “Premios Mejores Ideas 2014”, by Diario Médico, for the discovery of one of the causes of the idiopathic pulmonary fibrosis. The journal specialized in health also awarded a pioneer surgery carried out at the Vall d’Hebron Hospital and led by Dr. David García Dorado, head of the Cardiocirculatory Pathology group at VHIR. The research conducted by Dr. Morell determined that one of the main causes of the idiopathic pulmonary fibrosis is the exposure of occult avian antigens from commonly used feather bedding (eiderdown and pillows), as well as the exposure to birds and fungi in little but persistent quantities. These surprising results, published in The Lancet Respiratory Medicine, will help the prevention and early detection of this pathology, avoiding advanced stages. On the other hand, Dr. García Dorado coordinated a surgery on a 22 weeks’ pregnant woman, who suffered a congenital heart disease and was wearing a prosthesis that replaced the aortic valve. The prosthesis failed by the stress of the heart during the pregnancy, and consequently, she suffered heart failure and a severe stenosis that put her life and the fetus’ life at risk. The medical team successfully implemented an aortic prosthesis inside the prosthesis that she was already wearing, in order to repair it.  The Catalan national theater (TNC) hosted on Monday the XIII edition of these prizes that recognize outstanding institutions and professionals in the field of healthcare in the last year. Among the winners, the former responsible of the Alzheimer’s group at VHIR, Dr. Mercè Boada, was awarded for starting a phase III clinical trial that could modify the course of the disease and stop the cognitive impairment. </td></tr></table>comunica@vhir.org (VHIR)Tue, 4 Nov 2014 00:00:00 GMTThere are whishes that change the world (03/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=229&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0229\2014_0229_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Plaza de Los Pinazo of Valencia will host until November 4, the campaign “There are whishes that change the world” by Legado Solidario. Vall d’Hebron Institute of Research (VHIR) participates in this project with the aim to disseminate the possibility of leaving bequests and legacies to charities and nonprofit organizations. These types of donations have the aim to keep the commitment of those who die and want to support any of the 24 entities associated to the campaign, such as VHIR. The procedure that must be followed to formalize the legacy is inexpensive and simple, and respects the rights of the heirs. The image that represents VHIR is a pregnant woman who holds a picture of a newborn who clutches his parents hand with the slogan “Your legacy will give life to others”. Since the participation of VHIR in the campaign in 2012, 4 people have contributed to the biomedical research of excellence led at Vall d’Hebron, with two bequests and legacies.&nbsp; herencias. </td></tr></table>comunica@vhir.org (VHIR)Mon, 3 Nov 2014 00:00:00 GMTLa Marató de TV3 funds 5 projects in which VHIR participates (30/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=228&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0228\2014_0228_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> La Marató de TV3 on Neurodegenerative Diseases will fund 5 projects that will be carried out at the Vall d’Hebron Institute of Research (VHIR) and other research centers. A total of 44 research projects of scientific excellence will be funded with the 11 million euros raised in the 2013 edition. From the 5 projects granted, VHIR will lead 2: “Efecte terapèutic de liposomes conjugats a proteïna ApoJ/Clusterin recombinant en models experimentals de malaltia d'Alzheimer” Principal investigator: Dr. Mar Hernández-Guillamon, researcher of the Neurovascular Diseases group. Collaborator: Dr. José María Delgado from the Universidad Pablo de Olavide de Sevilla. Budget: 200,000 euros “El paper de la reelina en la cruïlla dels mecanismes moleculars de la malaltia d’Alzheimer: taupatia, toxicitat de l’amiloide i transmissibilitat” Principal Investigator: Dr. Lluís Pujadas, researcher of the Alzheimer’s group. Collaborator: Dr. José María Delgado, from the Universidad Pablo de Olavide de Sevilla Budget: 299.943 euros Besides these projects, VHIR will collaborate in 3: <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: #555555; background-color: transparent; text-decoration: non</td></tr></table>comunica@vhir.org (VHIR)Thu, 30 Oct 2014 00:00:00 GMTVHIR wins Best in Class 2014 to the best research and innovation center (29/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=226&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0226\2014_0226_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d'Hebron Institute of Research (VHIR) has received the Best in Class award to the best research and innovation center, one of the prizes organized by the journal Gaceta Médica and the Cátedra de Innovación y Gestión Sanitaria de la Universidad Rey Juan Carlos. The Unit of transplantations of haemopoietic progenitors at Vall d'Hebron University Hospital (HUVH) and the Multiple Sclerosis Center (Cemcat) also have been awarded in a ceremony in which were represented the best hospitals of Spain. This award fits perfectly with the aim of VHIR, which mission describes it as an institution that promotes and developes not only research but also biomedical innovation. VHIR does research to improve people's lives, and its researchers work to transfer to the society the knowledge they got investigating in the&nbsp; labs. Their results don't stay in the labs, but seek to be applied in patients in mid term. Dr. Joan Comella, VHIR's director, received the award in a cerimony that took place in the World Trade Center of Barcelona with the presence of the Catalan Health Minister, Dr. Boi Ruiz. </td></tr></table>comunica@vhir.org (VHIR)Wed, 29 Oct 2014 00:00:00 GMTDr. Ramón y Cajal has entered the Spanish Royal Academy of Doctors as a full member (29/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=227&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0227\2014_0227_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Santiago Ramón y Cajal, head of the Molecular Pathology Service and group at the Vall d’Hebron Institute of Research (VHIR), has entered the Spanish Royal Academy of Doctors as full member. The topic chosen for his speech was the challenge of the pathological and molecular heterogeneity of cancer, and the new paradigms of the research. In his speech, he reviewed the research lines that his group has developed during the last years, as well as the most relevant advances in this field. He also suggested a change in the structure of the research, based in the creation of multidisciplinary teams in order to manage the knowledge, and to coordinate and monitor the projects. During his lecture, Dr. Ramón y Cajal also explained that the research is advancing a lot in the knowledge of cancer. In fact in the field of Molecular Pathology, researchers are continuously describing new variants of tumors, and in the field of molecular biology, they are identifying genetic and biochemical alterations. </td></tr></table>comunica@vhir.org (VHIR)Wed, 29 Oct 2014 00:00:00 GMTDr. Laura Audí new president of the European Society for Paediatric Endocrinology (28/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=225&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0225\2014_0225_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Laura Audí, researcher of the Paediatric Endocrinology group at the Vall d’Hebron Institute of Research (VHIR), has been appointed president of the European Society for Paediatric Endocrinology (ESPE) until October 2015. She will act as a president in the meetings of the board of directors of this society that involves hundreds of experts in diseases related to growth, puberty, sexual development problems and other disorders of the hormone producing glands of the body. Her group has been a member of the ESPE for the last 40 years. The society was founded in 1962 with the aim to promote the highest levels of clinical care for infants, children and adolescents with endocrine problems throughout the world, including in less advantaged areas. Dr. Audí will also organize the next ESPE annual meeting, which is the reference meeting point in this field around the world, from the 1st to the 3rd of October 2015. The annual meeting will be hosted for the first time in Barcelona with the theme “improving patient care: a pluridisciplinary dialogue”. It is expected that more than 3,000 professionals will have the opportunity to exchange and listen to the last discoveries and new perspectives in this field, as they did in the 53rd edition that took place this year in Dublin, Ireland. </td></tr></table>comunica@vhir.org (VHIR)Tue, 28 Oct 2014 00:00:00 GMTThe Duchenne Parent Project Association awards a grant to VHIR researchers (28/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=134&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0134\2014_0134_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Duchenne Parent Project Association awarded on Tuesday one of the three grants for research projects about Becker and Duchenne Muscular Distrophy (DMD) to a team participated by Vall d’Hebron Institut de Recerca (VHIR) researchers, for the project “Study of the efficiency of drugs capable of restoring the dystrophin expression in myoblasts of patients suffering from DMD with nonsense mutations, analysis of the causes that condition the variability in the response and evaluation of strategies to increase this efficiency in human myoblasts and in the mdx mouse”. The project lasts 2 years and the aid amount is 25,000 euros for the first year and the same for the second, after evaluating the results from the first year. From the VHIR, the team counts on the Drs. Francina Munell, María José Pérez and Silvia Ferrer&nbsp; (Pediatric Neurology Unit), Jordi Barquinero (Advanced Therapy Unit), Elena Martínez-Sáez (Molecular Pathology group), and also the project will be developed together with the Hospital Universitari Vall d’Hebron (HUVH) and the IQS’ Grup d’Enginyeria de Materials (GEMAT), with the participation of Drs. Salvador Borros, David Sánchez-García and Ofir Arad. The project focuses in the analysis of the variability of the response of the new therapies destined to reestablish the dystrophin expression in patients suffering from DMD, specifically the one focused on correcting the nonsense mutations with PCT124 (Ataluren). The aim is to understand why some of these patients respond less to these treatments and to design new strategies destined to correct these problems. Describing the project, the researchers point that “the best way to approach it is through the collaboration of centers that have experience in neuromuscular diseases in a clinical and translational level with centers that have experience in disciplines that allow to address new mecanisms and strategies”. The DMD is considered a rare disease<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-s</td></tr></table>comunica@vhir.org (VHIR)Tue, 28 Oct 2014 00:00:00 GMTDonation for ALS, in memory of Francesc Bonvehí (27/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=224&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0224\2014_0224_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Friends and relatives of Francesc Bonvehí donated 1,288 euros for the research in Amyotrophic Lateral Sclerosis (ALS) carried out by the Peripheral Nervous System group, led by Dr. Josep Gámez at Vall d’Hebron Institute of Research (VHIR). Francesc Bonvehí i Trench had ALS and died because of this disease just a few hours after the collective ice bucket challenge that he promoted at the main square of Manresa at the end of September. That day, many friends and relatives got wet for his cause, many of them from his association “Grup Sardanista Dintre el Bosc” and from the “Geganters de Manresa”, in which he was the vice-president. The funds raised at the party were donated to the VHIR and to the Miquel Valls Foundation, which is a non-profit organization with the aim to improve the quality of life of patients with ALS. Dr. Gámez group is currently working on three different research lines dedicated to the study of molecular mechanisms and genetic mutations of the disease. The group is also part of ALSUntangled, an international network of clinical experts with the aim of offering alternative or off-label ALS treatments. Besides the research team, the Vall d’Hebron University Hospital has an interdisciplinary unit devoted to the care of ALS patients, which serve nearly 100 out of the 400 affected that are in Catalunya. The cause of ALS is unknown and there is no cure or treatment available. It is a debilitating disease characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Oct 2014 00:00:00 GMT"If you are a true scientist and confident about your data you will be the winner" (24/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=223&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0223\2014_0223_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Nobel Prize laureate in Medicine in 2005, Professor Barry J. Marshall, is the responsible of the paradigm shift in the treatment of stomach ulcers. For many years, the scientific community associated this disease with factors such as stress, and no one could conceive that bacteria could survive in the stomach. Prof. Marshall did it, but during 10 years he was much criticized. Eventually, he showed that the bacterium Helicobacter pylori is the cause of most peptic ulcers, and consequently, the disease can be cured with antibiotics.&nbsp; On October 19, Marshall gave the opening lecture of the World Health Summit 2014, where we met him to know more about his experience as a researcher. How did you feel when everybody said that you were wrong in that time? Were you frustrated, angry or just the opposite? My answer to that is that science is not a democracy. If you are a true scientist and you are confident about your own data, you don’t need to worry about everybody being against you. You know that eventually, you’ll be the winner. And the most simple, cost-effective solution to any problem is going to be the ultimate successful one. I knew that eventually everybody would want to use antibiotics. At that time, did you have the support of a PI or your boss? It took me two years of trying before I had any finding. And after that, I didn’t need any boss because I had my own money and my own salary from the Australian research funding agency. Peer review funding is good, but originally with a funny idea or strange theory you don’t have any peers, so you have to develop some collaborators or supporters. Then with the initial very small thing you do, that in my case was a post, you have a few supporters that will help you to talk to more senior people, who can mentor you, give you some advice and make suggestions. However, you don’t have to take the suggestions because they are often the guides. But that’s when you start, and that might connect you with the right networks. In my case, ultimately within two years, I had national and international supporters. In 1984 you drank a huge amount of helicobacters. What led you to do this? <span st</td></tr></table>comunica@vhir.org (VHIR)Fri, 24 Oct 2014 00:00:00 GMT"The recovery of Teresa Romero will foster the research in ebola" (23/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=222&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0222\2014_0222_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Doctor Diana Pou, member of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR) and the Catalan program for international health (PROSICS), is a consultant of the scientific committee of Ebola in Spain at the Instituto de Salud Carlos III (ISCIII) of the Spanish government. Pou worked in Africa with Médecins Sans Frontières for several periods in 9 years, and has experienced in first person 3 ebola outbreaks. For the specialist in tropical medicine, the recovery of the Spanish nurse assistant, Teresa Romero, “opens the door to the research in ebola”. According to the Spanish news agency EFE, she assured that pharmaceutical companies are who decide when will arrive the first drug for ebola. Nonetheless, since this case, “the expectations in the knowledge of the virus, the disease, the possible treatments and the vaccines have increased” Pou reported. The physician was interviewed in TV3 and 8TV, where she explained her experience as a consultant of the Spanish government. She also explained that there is still a long shot of new cases in Spain, and insisted on the need to manage what she considers an ‘epidemic of fear’ among the society. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Oct 2014 00:00:00 GMTStudy in young male prisoners suggest that aggression can be reduced by treating ADHD (22/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=221&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0221\2014_0221_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> At an international meeting held by the Aggressotype Consortium in Mainz, Germany, researchers from King’s College and Imperial College London presented preliminary results from an on-going treatment study of ADHD in young male prisoners. A team of researchers from the group of Psychiatry, mental health and addictions, at the Vall d’Hebron Research Institute (VHIR), led by Dr. Josep Antoni Ramos-Quiroga, is participating in this study through the Aggressotype Consortium. The preliminary results show that 20% of the prisoners met clinical criteria for ADHD. After medical treatment with a long acting stimulant medication there was a large reduction in ADHD symptoms. Improvements with ability to focus attention, restless over activity and impulsive responding were accompanied by greater self-control of behavior and ability to engage positively in educational and rehabilitation programs. Participants reported being less frustrated, irritable and angry, and there was a reduction in aggressive incidents. Aggressotype is a large international consortium funded by the European Union consisting of 18 academic and 6 commercial partners. Aggressotype researchers aim to unravel the biological causes and mechanisms underlying aggression in ADHD and conduct disorder and also investigate how aggression can best be prevented and treated. In their annual meeting this October, the 60 researchers discussed the progress made during a successful first year of their 5-year project, with issues presented covering a wide range of disciplines. Aggressotype represents a unique mix of people with skills and expertise in neuropsychiatry, neuropsychology, preclinical animal and in vitro models, neuroimaging and neurochemistry, genetics and genomics, epigenetics, bioinformatics and biostatistics, clinical pharmacology, regulatory affairs, ethics, valorisation and project management. </td></tr></table>comunica@vhir.org (VHIR)Wed, 22 Oct 2014 00:00:00 GMTThe project 'Global Tele Rehabilitation System' improves the mobility of patients after a stroke (21/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=220&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Global Tele Rehabilitation System project (GTRS), promoted by the Vall d’Hebron Research Institute (VHIR) with the support of Fundación Vodafone España, has developed a solution for patients after suffering a stroke that allows them to do the rehabilitation at home under the control of a medical team. After a year and a half of trials, the initiative has concluded with excellent results. The solution, created by the I2Cat Foundation, consists on a series of personalized exercises presented as a game that patients have to follow in order to improve mobility on the parts affected after the stroke. The system records the exercises to facilitate the evolution of treatment and includes programmed videoconferences so that doctors and patients can chat about the rehabilitation process. The system, from the patient side, consists of a computer equipped with a touch screen, a Microsoft Kinect sensor and a mobile broadband internet connection provided by the 4G Vodafone network. The application has been used by 30 patients from different ages that have a disability because of a stroke, and they have followed a treatment during four weeks in each one of the 4 available devices. Besides the devices, the Occupational Therapy Unit at the Vall d’Hebron University Hospital (HUVH), as well as the rehabilitation team lead by Dr. Inmaculada Bori, have had a key role in the clinical follow-up of the cases. Patients are really satisfied with the results of the day-to-day treatment. Now the pilot study is over, all the equipment will be incorporated to the normal practice to keep being of use to new patients. They are also studying the possibility of establishing these equipment in different rehabilitation centers. The study, that has just concluded and its results will be presented in the next congress of the Sociedad Española de Neurología, has shown that the use at home of the system GTRS during 4 weeks induces a general improvement in the mobility of upper extremities of patients. All participants, patients and professionals, have coincided in valuing positively the tool and most of them regretted not being able to use it longer. Dr. Marc Ribó, neurologist at the Ictus Unit of the HUVH, ensures that the system is “a step forward, which makes rehabilitation easier and saves time and money for the patient and for the public health system”. The challenge now is that the system also improves the mobility on inferior extremities, as well as using it for other disabilities. </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Oct 2014 00:00:00 GMTThe race 'Nick Horta' raises 8,000 euros for hepatic cancer (21/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=180&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0180\2014_0180_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The V Cursa Nick Sport d'Horta, the charity race that took place the September 21th and this year was dedicated to hepatic cancer at the Vall d’Hebron Institut de Recerca (VHIR), was a success with 1,000 runners registered and 8,000 euros raised for research on this disease, at VHIR. María José Moscoso, the promoter of the race, has given the cheque to VHIR's Director, Joan X. Comella, together with Gemma Flores, director of the Nick Sports center. Moscoso it’s been 9 months since she got a liver transplant at Vall d’Hebron, after she was diagnosed with hepatic cancer. The day of the race she gave a symbolic cheque to Dr. Ramon Charcho, head of the digestive transplants group at VHIR. “I feel that I must help all the people who have been with me and the Catalan public system of health”, said María José, that admitted that “I consider my duty to compensate somehow all the things that the doctors have done to keep me alive and healthy”. This is the reason why the last two years the charity race has dedicated all funds to the research at VHIR; the goal is to collect more funds than last year that raised nearly 5,000 euro. The main novelty for this year event was a free special race for young people and children with Down syndrome or any other disability that joined the race in the last 1.5km. </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Oct 2014 00:00:00 GMTVHIR researchers unveil the role of a key protein in the reparation of the damage caused by the solar radiation (16/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=218&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0218\2014_0218_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Melanoma group at the Vall d’Hebron Institute of Research (VHIR), integrated by professionals from the services of Dermatology, Oncology and Pathology, and led by Dr. Juan Ángel Recio, discovered that a protein, called LKB1, is essential to trigger the process of reparation of the DNA damage caused by solar radiation.&nbsp; The landmark, published in Plos Genetics, paves the way for the use of the protein as a prognostic factor in patients with ultraviolet induced skin cancer. Ultraviolet radiation has been associated to the acquisition of different types of skin cancer and premature skin aging. It causes modifications in the genetic material of cells (DNA) that if not repaired properly will lead to a mutated DNA which might trigger the development of cancer. In fact, several studies conclude that people who overexposed to the sun during their childhood are more likely to develop melanoma at the age of 50 and above. For that reason, understanding the molecular basis of the ultraviolet-induced DNA damage response is important to elucidate the mechanisms of skin tumorigenesis. The aim of the study was to determine the causes that lead to the development of skin cancer due to ultraviolet radiation. Particularly, they wanted to unveil how LKB1, which is a mutant protein in humans, participates in these processes. Firstly, the authors used a UV-induced skin cancer mouse model, where one of the two Lkb1 gene alleles was deleted, and consequently the amounts of LKB1 protein was of half the normal levels. A single dose of ultraviolet radiation in Lkb1 neonate mice was enough to induce the quick development of squamous cell carcinomas, and this was associated to a deficient response in DNA damage repair. This single dose of radiation is the equivalent to three hours of exposure to the sun without any protection in summer. The results were surprising, Dr. Recio reported, because the animals developed skin cancer five months before the expected date: “mice with the protein inactivated in one allel developed, in just one month, a type of cancer that use to suffer farmers, fishermen or people who has been exposed to the sun for a long period in their life”, explained Dr. Recio. Moreover, cells harboring the damaged DNA were resistant to cell death (apoptosis). Thus, as Dr. Recio said, lack of LKB1 promotes a double effect: “cells not only fail to repair the damage in their DNA, but they do not die, leading to the accumulation of mutated cells and the development of tumors”. The research team has obtained similar results (to be published soon) in two additional mouse models of melanoma, a much more lethal type of UV-induced skin cancer. In the near future, Dr. Recio’s team will be evaluating LKB1 as a prognostic risk factor for ultraviolet–induced skin cancer. They also are investigating the different factors that may alter LKB1 expression, with a particular emphasis in families with skin cancer predisposition or skin cancer history. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Oct 2014 00:00:00 GMTTwo VHIR platforms become facilities of the Spanish Map of Singular Scientific and Technical Infrastructures (16/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=219&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0219\2014_0219_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The council of Political Science, Technology and Innovation approved the new so-called Spanish Map of Singular and Technical Infrastructures (ICTS) that, for the first time, includes two platforms of the Vall d’Hebron Institute of Research (VHIR). These platforms are the Area of Functional Validation and Preclinical Research (FVPR), managed by the CIBBIM-Nanomedicine, and the Molecular Imaging Platform, located in the Animal Facilities of the Institute. Both infrastructures are integrated in the Spanish network of biomedical research in bioengineering, biomaterials and nanomedicine (CIBER-BBN). The FVPR aims to provide the industry and other research groups with an optimum technical platform for testing new biomedical applications based on the nanotechnology from compounds for the treatment of specific diseases to new applications in diagnosis and imaging. One of the services of the FVPR is the Molecular Imaging Platform, established through the common efforts of CIBER-BBN, CIBBIM-Nanomedicina and VHIR, as a service to research groups and pharmaceutical companies. Its mission consists in provide the capacity to develop noninvasive optical image in vivo at cellular, molecular and functional level, including fluorescence and bioluminescence. Both services are part, together with 27 Spanish infrastructures, of the NANBIOSIS platform, which is devoted to produce and characterize nanomaterials, biomaterials and biomedical systems at the CIBER-BBN. This platform is oriented towards medical applications and aims to give an easy full service to researchers. It includes the design, production of biomaterials and nanomaterials, the characterization of these materials and tissues, and the development of medical devices and systems from a physical, chemical, functional, toxicological and biological point of view, including the preclinical validation (which is the part carried out at VHIR). The new map approved by the government has 29 ICTS that include a total of 59 infrastructures. All of them passed a rigorous assessment process and demonstrated their economic sustainability. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Oct 2014 00:00:00 GMTThe town of Sant Mateu collaborates in the research against colorectal cancer (15/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=216&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0216\2014_0216_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Mamma Mia musical, played in Sant Mateu by an amateur company from Vinaròs, beat the expectations of the organizers, who counted nearly 2,000 visitors. It is in fact a high number of people, taking into account that this town located in the Maestrat has more or less the same number of inhabitants. The tickets were free, but instead, the party committee asked for donations to support the research in colorectal cancer carried out at the Vall d’Hebron Institute of Research (VHIR). They raised more than 4.300 euros that will fund the research of the Molecular Oncology group at CIBBIM, led by Dr. Diego Arango. Dr. Arango received in his lab the members of the party committee, in order to thank them for the initiative and to tell them the research that he leads at VHIR. His group works in two main research lines: one focused in the biology of the disease with the objective to personalize treatments, and the other one aims to identify biomarkers to improve the survival of colorectal cancer patients. </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Oct 2014 00:00:00 GMTAnnals of Neurology recognizes a study by Dr Vila as 'paper of the year' (15/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=217&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0217\2014_0217_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editorial board of the Annals of Neurology, the journal of the American Neurological Association, and its Editor-in-chief Prof. Clifford Saper, awarded the “Paper of the Year” prize to a study led by Dr. Miquel Vila, ICREA researcher, leader of the Neurodegenerative Diseases Group of the VHIR, and member of CIBERNED.&nbsp; The study shows that pathological forms of the alfa-synuclein protein present in the brain of deceased Parkinson Disease (PD) patients were capable of initiating a PD-like pathological process in mice and primates. For the authors, these findings provide new information on how the disease is initiated and amplified. The study, published in February 2014, in the Annals of Neurology, involved the participation of other CIBERNED groups from the University of Valencia and the University of Navarra, as well as researchers from the University of Bordeaux, France.&nbsp; The award will be presented during the next American Neurological Association meeting in Baltimore, Maryland, October 12-14.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Oct 2014 00:00:00 GMTExperts in the application of genomics in biomedicine meet at VHIR (14/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=214&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0214\2014_0214_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The meeting “The impact of genomics in translational medicine: present view”, held last Monday October 13 in the Vall d’Hebron Institut de Recerca (VHIR), brought together a group of experts in the application of genomic techniques in biomedicine with two main objectives: bring these techniques closes to our community, and analyzing how they apply and the problems said application bring. The first speaker, Dr. Joaquín Dopazo, heaf of the group of Computational Genomics at the Centro de Investigación Príncipe Felipe (CIPF), explained to the researchers of the institute how they can use different sequencing techniques in order to identify pathological variables in the genome of the patients. After his speech, Dr. Ivo Gut, director of the Centro Nacional de Análisis Genómico, approached some international projects in which genomic information is key for the better understanding of rare diseases and cancer. The third speaker, Dr. Manel Esteller, director of the Epigenetic and Biology of Cancer program at IDIBELL, recalled that the genetic effects are just one small part of the molecular causes of the disease, and that massive epigenetic analysis can have an important diagnostic value. Finally, Dr. Xavier de la Cruz, head of the Translational Bioinformatics research group at VHIR, presented the techniques for the identification of pathological mutations to the sequencing problems, its limits and possibilities of improvement. <p style=" text-align: left; text-indent: 0px; padding: 0px </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Oct 2014 00:00:00 GMTA day of hope for patients with multiple myeloma (14/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=215&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0215\2014_0215_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> More than a hundred patients with myeloma (bone marrow cancer) and their families took part on the 1st Meeting for patients in Spain, last Saturday in the Vall d’Hebron University Hospital, with the aim to open dialogue with the best researchers in the disease in Spain that are, also, among the world elite. The meeting was organized by Patient Power, the Vall d’Hebron Institute of Research (VHIR) and the Catalan Institute of Oncology. Doctors Mercè Gironella, responsible of Myeloma at the Vall d’Hebron Hospital and researcher at VHIR; Albert Oriol, from the Catalan Institute of Oncology; María Victoria Mateos, from the University Hospital of Salamanca; and Francesc Bosch, head of Hematology at the Vall d’Hebron Hospital and VHIR, sent an optimistic message. Dr Bosch explained that “at the rate we are going, we will be able to cure some cancers in 10 or 15 years”. Actually, treatments nowadays allow most of the patients a good quality of life during quite some years. Elisa, patient of myeloma for many years, explained that “I go ahead, have a normal life, even now that I have relapsed, and even at a time I lost my ability to walk”. Mercè, another patient, explained that it’s been 11 years since she was diagnosed and that she goes ahead “thanks to the doctors”. In the last years powerful medicine has been released that allow treating the patient once he or she relapses and, moreover, are less toxic than years ago. What is clear is that patients are now active part of the fight against the disease: “Before there was a tennis match between the doctor and the diseased; now it is a doubles match against the myeloma”<span style=" font-size: 8pt; </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Oct 2014 00:00:00 GMTVHIR selects Macrogen as the genomics service partner (13/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=212&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0212\2014_0212_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Institute of Research and the world-leading Genomics services company Macrogen announced that they had signed a comprehensive Genomics service partnership agreement including Macrogen X-Genome (the Xpressway to Genome) services. According to this agreement, Macrogen will provide various Genomics services including both the capillary sequencing service and the state-of-art next-generation sequencing (NGS) service to VHIR researchers. This agreement reinforces VHIR’ scientific and technical support services in an effort to strengthen its researcher’s capacity to discover and implement novel diagnosis and treatment measures. In this sense, VHIR’s researchers will benefit from the Macrogen-VHIR special program based on Macrogen’s comprehensive Genomics service portfolio. VHIR’s staff, composed of 1.200 researchers (mostly clinicians), is aimed to achieve a direct translation from research to applications, with the final goal of offering Vall d’Hebron Hospital patients the benefit of the most advanced knowledge. By means of this agreement, Macrogen will partner VHIR to achieve its objective. In fact, Macrogen is the only European provider of the Illumina HiSeq X Ten sequencing system based large-scale Human whole-genome sequencing service, also known as Macrogen’s ‘X-genome (the Xpressway to Genome)’ service. Optimized for large-scale human genome analysis projects, the HiSeq X Ten sequencing system is capable of analyzing the genomes of 16 people within 3 days for a cost of less than 1,000 dollars, giving rise to expectations that it will pave the way to a new era of human genome sequencing. In January of this year, Macrogen became the first commercial service provider to sign a preferred supply agreement for the HiSeq X Ten system with Illumina. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Oct 2014 00:00:00 GMTDr. Sanchez de Toledo, recognized with the highest distinction of Rotary International (13/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=213&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0213\2014_0213_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Rotary International has awarded the Paul Harris distinction to Dr. José Sánchez de Toledo, head of the Translational Researh in Child Cancer at the Vall d’Hebron Institute of Research (VHIR), as recognition to his scientific and human career dedicated to the cure of children with cancer, and beating the disease. The award is the highest recognition that Rotary International gives for business excellence, community service and professional career. The prize was presented last Thursday October 9 in Barcelona, in the context of the celebration of a charity dinner, to raise funds for the research group in child cancer at VHIR. Dr. Sánchez de Toledo gave a conference in the celebration titled “Research for children with cancer. A better future”. The organization brought together eminent people from the health field, public and private institutions, companies, rotary authorities and civil society in general. Dr. Sánchez de Toledo is Doctor in medicine and Surgery for the Universitat Autònoma de Barcelona (UAB). Nowadays he is chief of Pediatric Oncology and Hematology at the Vall d’Hebron University Hospital, head of the research group on child cancer at VHIR, and associated professor of pediatrics at UAB. The Service he leads was pioneer in Spain, in 1984, on performing bone marrow transplants on children. Since then, the transplant unit has realized more than 1,100 cell transplants, more than twice any other Spanish hospital. Among other recognitions, in 2012 he received the price to Professional Excellence that gives the Col·legi de Metges de Barcelona and was chosen Catalan of the Year 2012. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Oct 2014 00:00:00 GMTVHIR inaugurates the Master's Degree in Translational Biomedical Research (10/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=211&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0211\2014_0211_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> This Friday, October 10, the Vall d’Hebron Institute of Research (VHIR) has celebrated the opening day of the first edition of the Official Master’s Degree in Translational Biomedical Research. In the ceremony, a representative of Banco Santander, Pfizer, Promax, Fenin and the VHIR have given the 6 sponsored grants that will cover the full cost of registration to the students with the best qualifications. VHIR’s Director, Dr. Joan Comella, has transmitted to the 37 students enrolled in the master the passion, enthusiasm and illusion put by the researchers in the program; researchers that will train them in their specialties, as teachers of the master. The co-coordinator of the master, Dr. Anna Meseguer, has explained the details of the program that she has designed together with Dr. Francina Munell, with the aim of training researchers of excellence that will be able to contribute to the success of translational biomedical research in the future. The master is directed to a scientific career, gives access to the doctorate program, and offers the students the possibility of choosing an area in the biomedicine field in which to study and do their internships. At the ceremony were also present the Vice-Rector of Strategic Projects and Planification at UAB, Dr. Lluís Tort; the Assistencial Director at the Vall d’Hebron University Hospital, Dr. Jaume Roigé, and the Teaching Director at the Hospital, Dr. M. Josep Cerqueira. </td></tr></table>comunica@vhir.org (VHIR)Fri, 10 Oct 2014 00:00:00 GMTThe music parade La Murga de la Llagosta gets wet for ALS (09/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=206&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0206\2014_0206_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> For the first time in 30 years, the music parade “La Murga de la Llagosta” dedicated their celebration to the research in Amyotrophic Lateral Sclerosis (ALS), led at Vall d’Hebron Institute of Research (VHIR) by Dr. Josep Gámez. Antonio Melgar suffers this devastating disease and José Antonio Monterrubio’s mother died because of ALS. Both are members of “La Murga” and, coinciding with the successful Ice Bucket Challenge campaign, they decided to raise funds for research. Besides the music parade, they organized a big paella for all the participants, a contest of potato omelettes, a party for children and a concert of “habaneras”. With all these activities, they raised more than 1,100 euros that will fund the research carried out by the group of Peripheral Nervous System, led by Dr. Gámez. His group is currently working on three different research lines dedicated to the study of molecular mechanisms and genetic mutations of the disease. The group is also part of ALSUntangled, an international network of clinical experts with the aim of offering alternative or off-label ALS treatments. Besides the research team, the Vall d’Hebron University Hospital has an interdisciplinary unit devoted to the care of ALS patients, which serve nearly 100 out of the 400 affected that are in Catalunya. The cause of ALS is unknown and there is no cure or treatment available. It is a debilitating disease characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. </td></tr></table>comunica@vhir.org (VHIR)Thu, 9 Oct 2014 00:00:00 GMTVall d'Hebron professionals have successfully tested a pioneer surgery that reduces the effects of the spina bifida in the fetus (08/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=204&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0204\2014_0204_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Since 2011, professionals from the Vall d’Hebron University Hospital have operated fetus diagnosed with myelomeningocele or spina bifida, which is a congenital disorder that affects the central nervous system and, in life, results in paralysis of the lower extremities with difficulty or inability to walk, as well as sphincter incontinence. Until now, the procedures were very complex: surgeons opened the uterus of the pregnant women between months 4 and 5, operated the back of the fetus in order to correct the defect, and then closed again the uterus. However, since 2013, the same professionals have successfully tested a surgery that reduces the effects of the spina bifida in the fetus, using a pioneer technique called fetoscopy. This procedure is minimally invasive because it only goes through the fetus’ back with a tiny endoscope. Once the defect is corrected, researchers seal the injury with a technique conceived and developed by Dr. César Galo García Fontecha, head of the Bioengineering, Orthopedics and Surgery in Pediatrics group at Vall d’Hebron Institute of Research (VHIR). </td></tr></table>comunica@vhir.org (VHIR)Wed, 8 Oct 2014 00:00:00 GMTThere is a strong association between renal failure and triglyceride levels in people with diabetes (06/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=203&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0203\2014_0203_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> An international study, performed by 24 hospitals and clinics from 13 different countries, among them the Vall d´Hebron Institut of Research (VHIR), with&nbsp; Drs. Rafael Simó and Cristina Hernández, shows that the levels of lipids in diabetic patients are clearly associated with the risk of developing renal failure. The study was published in the journal Circulation.&nbsp; The goal of the research was to determine whether triglyceride and cholesterol levels in the plasma are associated with diabetic kidney disease (nephropathy) and vision loss (retinopathy). The study shows that triglyceride and HDL-C levels are strongly, and independently, associated with the risk of developing microvascular disease, and in particular, kidney failure. This means that, even if the levels of “bad” cholesterol (LDL-C) in these patients are controlled by drugs, the probability that they will develop kidney failure is increased if they have high levels of triglycerides, whereas HDL-C diminish it. Triglycerides are a type of fat with a different function than cholesterol (they are a source of energy) and, when in high levels, can cause artherosclerosis and heart disease.&nbsp; As Dr. Simo points out, “controlling the levels of triglycerides not only decreases the cardiovascular risk but also curbs kidney disease, which is the main cause of end-stage renal disease and transplantation, with the economic cost it implies for the health system”. The risk of retinopathy is also associated with triglyceride levels, but the association is weaker and may depend on other factors such as hypertension and glycosilated hemoglobolin levels.&nbsp; For the authors, the strength of this study relies on its global scope: the multiple sites and the size of the sample (2635 cases and 3683 controls) supports wide applicability of the results across different regions and ethnical groups. Diabetes mellitus is the main cause of kidney failure and blindness in adults. Its worldwide prevalence is on the rise, and the complications associated to the disease are also expected to increase. Even though glucose and tension control can limit the development of diabetic microvascular disease, the residual risk for these complications remains high. Therefore, it is necessary to identify other targets and treatments to make progress in slowing the development of diabetic kidney disease and retinopathy.&nbsp; <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transpa</td></tr></table>comunica@vhir.org (VHIR)Mon, 6 Oct 2014 00:00:00 GMTVall d'Hebron launches the second fundraising campaign in the hospital grounds (03/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=202&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0202\2014_0202_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) launched this week a fundraising campaign in the hospital facilities. During the following weeks, a team of fundraisers will inform the users and their companions about the opportunity to actively collaborate in the research carried out by their doctors. The Fundraising Unit of the VHIR launched this second campaign in order to attract new donors who will help to fund the training of pre-doctoral researchers. In the first campaign, more than 300 people became ‘friends of VHIR’. Thanks to them, two researchers will work and do their dissertation at the Institute in the next 3 years. The campaign started in the General Area and will also take place in the Maternal &amp; Child and Trauma &amp; Surgery areas, until November 28th. </td></tr></table>comunica@vhir.org (VHIR)Fri, 3 Oct 2014 00:00:00 GMT'Friends of VHIR' fund the pre-doc training of two researchers (02/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=201&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0201\2014_0201_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The 2013 call of the VHIR’s Programme for PhD students granted two additional researchers, Casandra Riera and Luz Jubierre, thanks to the donations of ‘friends of VHIR’. Casandra is graduated in Biotechnology at the Universitat Autònoma de Barcelona and holds the Master Degree in Molecular Biology of the Universitat de Barcelona. On 2012, she joined the Translational Bioinformatics group, led by Dr. Xavier de la Cruz, in order to carry out a project for the development of bioinformatic tools for the prediction of pathological mutations. Her dissertation will focus on this project for the next 3 years.  Luz is graduated in Biomedical Sciences at the Universitat the Barcelona and holds the Neurosciences Master Degree of the same university. Since 2012, she has done a stage with the Translational Research in Child Cancer group, coordinated by Dr. Josep Sánchez de Toledo, combining her studies of the double degree in Mathematics and Physics of the Universitat de Barcelona. Her dissertation, led by Dr. Miguel Segura, will be focused on epigenetic therapies against two types of child cancer: neuroblastoma and ependimoma. Both researchers started their grant funded by ‘friends of VHIR’ on October 1st, together with the four researchers who were also granted by the Institute in this 2013 edition. </td></tr></table>comunica@vhir.org (VHIR)Thu, 2 Oct 2014 00:00:00 GMTPeople with irritable bowel syndrome present increased activation of immune defenses in their small intestine (01/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=199&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0199\2014_0199_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A team of VHIR researchers, led by Dr. Javier Santos and Dr. Maria Vicario, has discovered that people with diarrhea-predominant irritable bowel syndrome (IBS-D) present increased immune activity in their small intestine as compared to healthy persons. The results of the study have been recently published in the journal Gut and highlighted in the November issue of Nature Reviews, Gastroenterology and Hepatology. "Surprisingly, we have detected that patients with the disease have a higher number of antibody-producing cells in their jejunum than healthy subjects" explains Dr. Vicario. The majority of these antibodies are IgG immunoglobulins (Ig), which are more efficient than other types of Ig and are produced upon stimulation of B cells by specific antigens. By performing gene expression analysis, the research team revealed previously undescribed alterations at the molecular and cellular level that are associated to the clinical manifestations of the disease. "We found that the more activated the defenses in the intestine of these patients, the more severe are the symptoms", points out Dr. Vicario. The main symptoms of IBS are lower abdominal pain and modifications in stool frequency and consistency. To date, diagnosis of SII is established solely on the basis of clinical criteria and exclusion of other diseases.&nbsp; No reliable biomarkers exist, reason for which Dr. Santos underlines that "the results obtained in this study pave the way to the design of a test, based on the detection of immune activity in the intestine, to facilitate IBS diagnosis". The increased immune activation is detected in the small intestine but not in the blood of these patients, which indicates that it is a local event and explains why routine clinical analysis in these patients are often absolutely normal. IBS is a chronic and debilitating disease that affects approximately 15% of the population in developed countries. The chronicity of the disease, together with the lack of efficient therapies, significantly decreases the patient’s quality of life and represents a considerable health-care cost for society. </td></tr></table>comunica@vhir.org (VHIR)Wed, 1 Oct 2014 00:00:00 GMTVHIR Annual Report 2013 (30/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=198&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Welcome to the 2013 VHIR’s Annual Report: 20 Years committed to your health. Here you will find an interview with all the members of our Research Executive Committee and the manager director of HUVH, reviewing a year in which our institute is celebrating its 20th anniversary. This year you can watch videos of our research areas, explaining the activity of the different groups, and also images of the best of the innovation contest and a summary of the launching of the Master Degree in Translational Biomedical Research. Once again our scientific production –over the 4,000 total impact factor- and the findings of our researchers make of us one of the best and we want to share with you our most outstanding results. Links: - Multimedia Annual Report 2013 - Printable Annual Report 2013 <p style=" text-align: left; text-indent: 0px; padding: 0px 0px 0px 0px; margi</td></tr></table>comunica@vhir.org (VHIR)Tue, 30 Sep 2014 00:00:00 GMTPassengers aboard the Barcelona-France AVE learn how to use a defribillator (29/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=197&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0197\2014_0197_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Shock, Organ Dysfunction &amp; Resuscitation (SODIR) group of the Vall d’Hebron Institut de Recerca (VHIR) and the Intensive Care Unit of the Vall&nbsp; d'Hebron University Hospital joined the initiative “Un train d’avance pour la vie”. During 4 days more than 250 volunteers, trained by intensivist MDs, medical residents, nurse personnel and medicine students, taught Basic Life Support techniques and external semiautomatic defribillation to passengers travelling in the high-speed trains connecting Barcleona to Paris, Marseille, Lyon and Toulouse. The Catalan Society of Critical and Intensive Medicine appointed the SODIR researcher Dr. Juan Carlos Ruiz, as coordinator of the Basic Life Support and Resuscitation, together with Dr. A. Lesmes, project manager of the Plan Nacional de Reanimación Cardiopulmonar of the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC),&nbsp; to train the healthcare professionals that volunteered for the activity. With this action, intensive care specialists aimed to sensitize and familiarize the population with cardiopulmonary resuscitation procedures and the use of semiautomatic defribillators, so they can act in case of cardiac arrest. The initiative is led by LIFE Priority, a foundation belonging to the European Society of Intensive Care Medicine, that is currently celebrating its 27th Annual Congress in Barcelona. The World Heart Day is celebrated this Monday, and its goal is to promote preventive measures and raise awareness on the fight against cardiovascular diseases that, according to the World Heart Federation, are the first cause of mortality worldwide, causing 17.3 million deaths per year.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Mon, 29 Sep 2014 00:00:00 GMTThree VHIR professionals receive the Josep Trueta health merit medal 2014 (26/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=196&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0196\2014_0196_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Ferran Morell, head of the Pneumology group; Dr. Lluís Cabero, co-responsible of the Maternal Fetal Medicine group; and Dr. Mercè Canela, from the General Surgery group, have been awarded the health merit medal 2014, that give the Catalan Government. The awards ceremony has been presided by the catalan health regional minister, Boi Ruiz, with the vice-president of the Catalan Parliament, Núria de Gispert, in charge of giving the awards and closing the ceremony. The aim of the awards, which in this edition have been given to 9 people and 3 organizations, is to recognize their contribution to the advance and improvement of health. These awards were created in 1997, coinciding with the celebration of the centenary of the birth of the recognized Catalan doctor and scientist. Dr. Lluís Cabero Roura is co-responsible of the Maternal Fetal Medicine group, at the Vall d’Hebron Institut de Recerca (VHIR), and gynecologist at the Vall d’Hebron University Hospital. Degree in Medicine and Surgery from the UB, Doctor in Medicine and Surgery, and in Sciences and Biology. He was president of the Spanish Society of Gynecology and Obstetrics (1995-2003), president of the National Commission of Obstetrics and Gynecology of the Ministry of Education and Health (2000-2005), and president of the Commission Hospital Amic dels Nens UNICEF (1997-2006). He has also been vice-president of the MS Foundation and vice-president of the International Federation of Gynecology and Obstetrics (FIGO). Since 2009, he is Chair of the Capacity Building in Education and Training Committee de FIGO. He has also been appointed honorary member of several international societies. Nowadays, and since 1990, he is head of the service and Professor of Obstetrics and Gynecology at the Universitat Autònoma de Barcelona (UAB). Since 2000, he is director of the Obstetrics and Gynaecology Service at Quirón Clinic in Barcelona, and also presides the Bioethics Commission of the Spanish Society in the same clinic. Dr. Mercè Canela, from the General Surgery group at VHIR, is head of the Thoracic Surgery Service at the Vall d’Hebron University Hospital, and the reference in Catalunya for lung transplantation. Doctor of Medicine for the Universitat Autònoma de Barcelona. She is specialist in thoracic surgery. After working in different hospitals in Catalunya, on 1985 she joined the Germans Trias Hospital, where she became Clinical Chief of the Thoracic Surgery unit in 1995. She later joined the Vall d’Hebron University Hospital, where she achieved the maximum responsibility in the service, since 2009. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-styl</td></tr></table>comunica@vhir.org (VHIR)Fri, 26 Sep 2014 00:00:00 GMTThe world ultra trail champion sponsors the 6th race 'Los calderones' (23/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=195&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0195\2014_0195_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On October 5th will take place the 6th edition of the race ‘Los calderones’, sponsored this time by the world ultra trail champion, Luis Alberto Hernando. All the funds collected will be delivered to the research in child cancer led at Vall d’Hebron Institute of Research (VHIR) by Dr. Josep Sánchez de Toledo. The dog training association ADCAN organizes once again this race with several options: a mountain race run, a crosscan, a race for children and a walk through the mountain. All these disciplines will take place in Otero de las Dueñas, a town located in the northeast of León. The organizers and the sponsor of the race visited today the children with cancer admitted to Vall d’Hebron University Hospital. They gave T-shirts to all of them in order to transmit to them their motivation and determination to succeed: “I wanted to told them what makes me run in races of more than 100 kilometers”, said the athlete Luis Alberto Hernando. Dr. Sánchez de Toledo expressed to the organizers of the race the appreciation of his research team for the 8,000 euros that they have raised since the first edition in 2008. </td></tr></table>comunica@vhir.org (VHIR)Tue, 23 Sep 2014 00:00:00 GMT"Among the clouds a clearing", third VHIR's Scientific Beer (22/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=194&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0194\2014_0194_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The third Scientific Beer is ready. We invite you to attend to the third Scientific Beer, next October 7, organized by the Patronage unit at Vall d’Hebron Institut de Recerca (VHIR), with the collaboration of Damm and TheDoctorFactory. After achieving an eight-thousand and finding a needle in a haystack, this time we look at the sky and find a clearing through the clouds. What does a storm mean in science? And in economics? Can we make predictions without creating alarm? Being able to distinguish between a downpour and a tsunami is a challenge that is part of both scientific and economic worlds. To solve all these questions, and the wants that may arise, we have three guests to offer their points of view: Patricia Pozo-Rosich. Neurologist at the Hospital Universitari Vall d’Hebron and head of the research group of Headache and Neurological pain at VHIR. Ricard Pujol. Head of the Immunology service at Hospital Universitari Vall d’Hebron and the Immunology research group at VHIR. Research advisor at the ICS. Vicente Ortún. Dean and professor at the Faculty of Economic Sciences at UPF. Researcher, exdirector and founder of the Centre d’Economia i Salut (CRES). Lluís Amiguet, journalist, La Contra on La Vanguardia, will moderate the third talk. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-</td></tr></table>comunica@vhir.org (VHIR)Mon, 22 Sep 2014 00:00:00 GMTThe European Medicines Agency grants the "orphan drug" designation to a viral vector tested in VHIR (19/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=193&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0193\2014_0193_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The European Medicines Agency (EMA) approves the first viral vector for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a rare and lethal autosomal recessive hereditary disease caused by defects in nucleoside metabolism. The project is the result of a collaboration between the Neuromuscular and Mitochondrial Pathology Group, led by Dr. Ramon Martí, and the Gene and Cell Therapy Group, led by Dr. Jordi Barquinero.&nbsp; The disease is caused by mutations in the TYMP gene that encodes for thymidine phosphorylase, an enzyme involved in pyrimidine metabolism. A loss of this enzyme´s activity results in the accumulation of thymidine and deoxyuridine in the organism, which is particularly toxic to mitochondrial DNA synthesis. Disease symptoms generally appear in the second decade of life, with alterations in gastrointestinal motility and neurological defects, leading to progressive cachexia. To date, safe and efficient long-term treatments for the disease are lacking. Bone marrow transplantation from a healthy donor is the only treatment that has shown a positive effect, but the use of this procedure is extremely limited by the lack of donors and the high mortality rates observed in these patients.&nbsp; Using a mouse model of the disease, the VHIR researchers showed a potent effect when transferring bone marrow cells transduced with a viral vector containing a functional version of the TMYP gene. “However” Dr. Barquinero points out “given the high toxicity of bone marrow transplantation in MNGIE patients we decided to test a safer approach based on a liver-specific vector that had been successfully used in patients with hemophilia”. The researchers say that results obtained with the AAV-TYMP vector in the animal model, in collaboration with Dr. M. Zeviani from the Medical Research Council, Cambridge, are even more encouraging, as one single i.v. injection of the vector permanently corrects the metabolic defect in mice. The next step is to translate these results to the clinics. The designation of the vector as an orphan drug by the EMA will now allow the VHIR researchers to build an international consortium to apply for the European Program Horizon 2020 call on New Therapies for Rare Diseases. The consortium, whose main goal is to design and conduct a clinical trial, will be coordinated by Dr. Martí and includes other European groups, as well as the laboratory of Dr. M. Hirano, one of the leading experts in the disease, at the Columbia University in New York, and Genethon, a french non profit organis ation that will produce the vector in GMP conditions for its use in the clinics.&nbsp;&nbsp;&nbsp;&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 19 Sep 2014 00:00:00 GMTVHIR is holding a Multiple Myeloma patient education event (18/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=191&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0191\2014_0191_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Multiple myeloma is a cancer that starts at the bone marrow blood cells. In the last few years, important progress has been made in its treatment thanks to research, offering new hope to patients and their families. To report on this advances Vall d’Hebron Institute of Research (VHIR), together with online cancer patients community Patient Power and the collaboration of the Catalan Institute of Oncology (ICO), is holding an educational event for myeloma patients. The event will take place on Saturday October 11 at Vall d’Hebron Teaching Pavillion from 10 AM. Top researchers will speak at the event, such as Dr Mercè Gironella, Hematology doctor and head of Myeloma research at Hospital Universitary Vall d'Hebron and Dr Francesc Bosch, Head of Onco-Hematology and Experimental Hematology Research Group in the VHIR. The goal is that myeloma patients learn about what is being done in research and they can exchange views with other patients and researchers. An oncology nurse and a psycho-oncologist will also advice patients on how to deal with treatment side effects and how to manage emotions during the cancer journey. The researchers that will speak at the event are: - Dr Mercè Gironella. Hematology doctor and head of Myeloma research at Hospital Universitari Vall d'Hebron since 2010. - Dr Francesc Bosch. Head of Onco-Hematology and Experimental Hematology Research Group in VHIR. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style:</td></tr></table>comunica@vhir.org (VHIR)Thu, 18 Sep 2014 00:00:00 GMTThe series of conferences on Rare Diseases arrives at Madrid (17/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=189&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0189\2014_0189_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> With Dr. Llera this Wednesday, September 17, resume the first series of conferences on rare diseases organized by the Vall d’Hebron Institute of Research (VHIR). Also, with this seminar, the cicle arrives at Madrid, as by now all have taken place in Barcelona. Dr. Llera’s conference, Optimizing the investigation processes on rare diseases and orphan drugs, is the seventh seminar programmed about rare diseases, and is 8 out of the 12 seminars that the Fundación Areces sponsors that will take place in Barcelona and Madrid, coinciding with the 20th anniversary of the Institute. The next seminar will be in Barcelona, on September 23, with Dr. Jordi Llinares, Head of Department-Product Development Scientific Support European Medicines Ageny, London (United Kingdom). And the next event in Madrid will be on October 29 with Dr. Ségolène Aymé, chair of the Topical Advisory Group for Rare Diseases Orphanet and director of the Insitut Nationale de la Santé et de la Recherche Médical (France). Until now, the hospital has hosted half of the seminars, with Dr. Ignacio Burgos, driver and coordinator of the rare diseases workshop at the Senate; Dr. Alastair Kent, director at the Genetic Alliance UK; Dr. Christoph Klein, Physician-in-Chief and Chairman at the Dr. von Hauner Children’s Hospital in Munich (Germany); Dr. Paul Lasko<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; text-deco</td></tr></table>comunica@vhir.org (VHIR)Wed, 17 Sep 2014 00:00:00 GMTVall d'Hebron establishes international basis for the management of respiratory infections in critical patients (16/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=188&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0188\2014_0188_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Jordi Rello, head of the Intensive Care Service and the Clinical Research/Innovation in Pneumonia &amp; Sepsis (CRIPS) group at Vall d’Hebron Institute of Research (VHIR), and head of the Intensive Care Service at the Hospital Universitari Vall d’Hebron, has set the foundations for a new model to guide the management of intensive care patients that have developed respiratory infections associated to mechanical ventilation. The conclusions of the study have been published at The Lancet Respiratoy Medicine and have been presented recently at the ERS International Congress , held in Munich, Germany. The researcher from VHIR and the Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), together with a researcher from the Hospital de Clinicas in Porto Alegre, Brasil, and a researcher from Brisbaine, Australia, has revised nearly a thousand articles published the last decade about pneumonia and tracheobronchitis caused by mechanical ventilation received in the ICU. Thanks to this basis, according to Dr. Rello, “the study establishes a new paradigm with the progress made the last 10 years that will guide a new approach to the managing of these patients in the next 5 or 10 years”. The infection of the airways is the main cause of antibiotic administration at the ICU and it usually presents in the form of severe sepsis or septic shock in patients that receive mechanical ventilation. The study shows that nearly 30 per cent of these infections evolve to pneumonia and the 70 per cent in tracheobronchitis, but finds that their differentiation is difficult because it depends on a lot of variables. The article describes for the first time the differences between the 8 main pathogens and shows how many days it takes pneumonia to appear after intubation, based on data not published of the largest European collaboration network in the study of this disease, the EUVAP. </td></tr></table>comunica@vhir.org (VHIR)Tue, 16 Sep 2014 00:00:00 GMT